An Update on Treatment Options for Primary Sclerosing Cholangitis

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):

Share By

An Update on Treatment Options for Primary Sclerosing Cholangitis Publisher

Iravani S^{1, 2} ; Dooghaiemoghadam A³ ; Razavikhorasani N³ ; Moazzami B³ ; Beirami AD⁴ ; Mansourghanaei A⁴ ; Majidzadeha K¹ ; Mehrvar A¹ ; Khoshdel A¹ ; Toosi MN³ ; Sadeghi A⁴

Source: Gastroenterology and Hepatology from Bed to Bench Published:2020

Abstract

Primary sclerosing cholangitis is a chronic cholestatic liver disease defined by strictures of the biliary tree which could ultimately lead to liver cirrhosis and cholangiocarcinoma. Although the exact underlying etiology of this disorder is not fully understood, the pathology is believed to be caused by immune mediated mechanisms. Growing body of evidence suggests several treatment modalities mainly focusing on the inflammation aspect of this disorder. However, there is still no consensus regarding the best treatment option for these patients. Thus, the present study aimed to review the current treatment options for patients with primary sclerosing cholangitis. © 2020 RIGLD, Research Institute for Gastroenterology and Liver Diseases.

Related Docs

View other Related Docs

1. Psc Associated Inflammatory Bowel Disease: A Distinct Entity, Expert Review of Gastroenterology and Hepatology (2022)

2. A Triple Blinded, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis: A Pilot Study, Journal of Gastrointestinal and Liver Diseases (2016)

3. The Clinical Significance of Biliary Findings in Magnetic Resonance Enterography of Patients With Inflammatory Bowel Disease, Polish Journal of Radiology (2022)

Experts (# of related papers)

View all Related Experts

Mohsen Nasiri Toosi (3)

Somayyeh Asghari (1)

Other Related Docs

4. Cholangiocarcinoma: State of the Art, Journal of Gastrointestinal Cancer (2020)

5. Ascariasis in Common Bile Duct Resulting in a Subhepatic Abscess, Acta Gastro-Enterologica Belgica (2020)

6. The Relationship Between Covid-19 and Auto-Immune Hepatitis: An Infectious Agent or Cause for Deterioration?, Archives of Clinical Infectious Diseases (2025)

7. Efficacy and Safety of Ppar Agonists in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, BMC Gastroenterology (2025)

8. Comparison of Coagulation Conditions in Patients With Liver Cirrhosis Due to Primary Sclerosing Cholangitis and Nonbiliary Causes of Cirrhosis Before Orthotopic Liver Transplant, Experimental and Clinical Transplantation (2020)

9. Bioinformatics Analysis Reveals Shared Molecular Pathways for Relationship Between Ulcerative Colitis and Primary Sclerosing Cholangitis, Genomics and Informatics (2025)

10. Vitamin D Is Associated With Clinical Outcomes in Patients With Primary Biliary Cholangitis, Nutrients (2022)

11. Comparison Between Brush Cytology and Forceps Biopsy Under Fluoroscopic Guidance for the Diagnosis of Proximal Cholangiocarcinoma, Middle East Journal of Digestive Diseases (2020)

12. Relationship Between Gallstone and Biliary Tract Neoplasm; a Systematic Review and Meta-Analysis of Cohort and Case-Control Studies, Immunopathologia Persa (2025)

13. Temporary Trans-Jejunal Hepatic Duct Stenting in Roux-En-Y Hepaticojejunostomy for Reconstruction of Iatrogenic Bile Duct Injuries, Trauma Monthly (2016)

14. Vanishing Bile Duct Syndrome-Related Jaundice As the First Presentation of Hodgkin Lymphoma, Radiology Case Reports (2023)

15. Igg4 Subclass and Gamma-Glutamyl Transferase in Children With Ulcerative Colitis With Primary Sclerosing Cholangitis and Without Sclerosing Cholangitis, Clinical and Experimental Hepatology (2019)

16. Four-Year Report of Iatrogenic Bile Duct Injury Repair From a Referral Hepatobiliary Center, Middle East Journal of Digestive Diseases (2024)

Style	Citing Format
MLA	Iravani S, et al.. "An Update on Treatment Options for Primary Sclerosing Cholangitis." Gastroenterology and Hepatology from Bed to Bench, vol. 13, no. 2, 2020, pp. 115-124.
APA	Iravani S, Dooghaiemoghadam A, Razavikhorasani N, Moazzami B, Beirami AD, Mansourghanaei A, Majidzadeha K, Mehrvar A, Khoshdel A, Toosi MN, Sadeghi A (2020). An Update on Treatment Options for Primary Sclerosing Cholangitis. Gastroenterology and Hepatology from Bed to Bench, 13(2), 115-124.
Chicago	Iravani S, Dooghaiemoghadam A, Razavikhorasani N, Moazzami B, Beirami AD, Mansourghanaei A, Majidzadeha K, et al.. "An Update on Treatment Options for Primary Sclerosing Cholangitis." Gastroenterology and Hepatology from Bed to Bench 13, no. 2 (2020): 115-124.
Harvard	Iravani S et al. (2020) 'An Update on Treatment Options for Primary Sclerosing Cholangitis', Gastroenterology and Hepatology from Bed to Bench, 13(2), pp. 115-124.
Vancouver	Iravani S, Dooghaiemoghadam A, Razavikhorasani N, Moazzami B, Beirami AD, Mansourghanaei A, et al.. An Update on Treatment Options for Primary Sclerosing Cholangitis. Gastroenterology and Hepatology from Bed to Bench. 2020;13(2):115-124.
BibTex	@article{ author = {Iravani S and Dooghaiemoghadam A and Razavikhorasani N and Moazzami B and Beirami AD and Mansourghanaei A and Majidzadeha K and Mehrvar A and Khoshdel A and Toosi MN and Sadeghi A}, title = {An Update on Treatment Options for Primary Sclerosing Cholangitis}, journal = {Gastroenterology and Hepatology from Bed to Bench}, volume = {13}, number = {2}, pages = {115-124}, year = {2020} }
RIS	TY - JOUR AU - Iravani S AU - Dooghaiemoghadam A AU - Razavikhorasani N AU - Moazzami B AU - Beirami AD AU - Mansourghanaei A AU - Majidzadeha K AU - Mehrvar A AU - Khoshdel A AU - Toosi MN AU - Sadeghi A TI - An Update on Treatment Options for Primary Sclerosing Cholangitis JO - Gastroenterology and Hepatology from Bed to Bench VL - 13 IS - 2 SP - 115 EP - 124 PY - 2020 ER -

Science Communicator Platform

Authors

Abstract